CRVO ▲ +1.6% - CervoMed Inc. $CRVO - CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFTD 2026 CervoMed shares rose 1.6% following the company's announcement that initial Phase 2a trial results for neflamapimod in nonfluent variant primary progressive aphasia have been accepted for presentation as a late-breaking oral session at the 2026 International Society of Frontotemporal Dementia conference, a venue that typically features significant clinical advances in neurodegenerative disease research. 10-SEP-2026 07:30 AM ET